Related Experiment Video
Updated: Apr 26, 2026
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Familial combined hyperlipidemia: consensus document]
Pedro Mata1, Rodrigo Alonso2, Antonio Ruíz-Garcia3
1Fundación Hipercolesterolemia Familiar, Madrid, España.
Insights
Familial combined hyperlipidemia (FCH) is a common genetic disorder linked to early heart disease. Early diagnosis and management of FCH, along with other risk factors like diabetes and hypertension, are crucial for patient health.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Metabolic Disorders
Background:
- Familial combined hyperlipidemia (FCH) is a prevalent genetic disorder frequently associated with premature coronary artery disease.
- It exhibits autosomal dominant inheritance, though a single causative gene has not been identified.
- Diagnosis relies on clinical criteria including lipid phenotype variability and a family history of hyperlipidemia.
Framework:
- FCH often co-occurs with type 2 diabetes mellitus, arterial hypertension, and central obesity.
- Patients with FCH are categorized as high cardiovascular risk.
- Lipid targets include LDL-cholesterol <100 mg/dL, and <70 mg/dL if cardiovascular disease or type 2 diabetes is present.
Implementation:
- Lipid-lowering treatment for FCH typically involves potent statins, potentially in combination with other agents.
- Comprehensive management of co-existing cardiovascular risk factors, such as type 2 diabetes and hypertension, is essential.
- This guidance offers recommendations for the diagnosis and integrated treatment of FCH.
Implications:
- Effective management of FCH and associated risk factors can significantly reduce the burden of cardiovascular disease.
- Specialists and general practitioners can utilize these recommendations for improved patient care.
- Optimizing treatment strategies for FCH is vital for preventing cardiovascular events.
Abstract:
Familial combined hyperlipidemia (FCH) is a frequent disorder associated with premature coronary artery disease. It is transmitted in an autosomal dominant manner, although there is not a unique gene involved. The diagnosis is performed using clinical criteria, and variability in lipid phenotype and family history of hyperlipidemia are necessaries. Frequently, the disorder is associated with type2 diabetes mellitus, arterial hypertension and central obesity. Patients with FCH are considered as high cardiovascular risk and the lipid target is an LDL-cholesterol <100mg/dL, and <70mg/dL if cardiovascular disease or type 2 diabetes are present. Patients with FCH require lipid lowering treatment using potent statins and sometimes, combined lipid-lowering treatment. Identification and management of other cardiovascular risk factors as type 2 diabetes and hypertension are fundamental to reduce cardiovascular disease burden. This document gives recommendations for the diagnosis and global treatment of patients with FCH directed to specialists and general practitioners.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
01:26Atherosclerosis III: Management
01:25Lipid Catabolism
01:06Lipid Digestion